Healthcare M&A Sentiment: Optimism Returns, but Discipline Defines the Next Cycle

Healthcare M&A sentiment is improving as the industry moves toward 2026, supported by stabilizing financing markets, renewed strategic interest, and growing confidence that the post-2021 slowdown has largely bottomed out. U.S. healthcare deal volume increased from $1.23 trillion in 2024 to $1.31 trillion in 2025, representing a 6% year-over-year increase, according to McKinsey. While activity remains below the $1.78 trillion peak reached in 2021, the recovery suggests buyers are gradually returning to the market after several years of caution.

Industry research from McKinsey, PwC, and KPMG points to a similar conclusion: healthcare organizations continue to pursue acquisitions to strengthen capabilities, improve operational efficiency, expand into attractive subsectors, and position themselves for long-term growth. However, unlike previous M&A cycles fueled by abundant capital and multiple expansion, today's market is defined by discipline, operational scrutiny, and a greater emphasis on execution.

Yet despite improving sentiment, significant obstacles remain.

According to Healthcare150's proprietary survey of 160 healthcare executives, investors, and operators, healthcare M&A faces three nearly equal barriers to acceleration. Regulatory and antitrust scrutiny was identified by 37% of respondents as the single largest obstacle, followed by valuation gaps between buyers and sellers at 32%, and a lack of scalable, high-quality assets at 31%.

The close distribution across all three categories is notable. It suggests healthcare M&A is no longer being constrained by one dominant issue such as financing availability or interest rates. Instead, buyers are navigating multiple structural challenges simultaneously.

Regulatory pressure remains particularly significant. Increasing scrutiny from regulators has lengthened transaction timelines and increased uncertainty around approval outcomes. At the same time, valuation expectations remain difficult to reconcile. Many sellers continue to benchmark pricing against the elevated multiples seen during the 2020–2021 investment cycle, while buyers are underwriting assets based on today's realities of reimbursement pressure, labor inflation, and margin compression.

The third finding may ultimately prove the most important. Nearly one-third of respondents believe the market simply lacks enough institutional-quality assets capable of supporting large-scale consolidation strategies. This suggests that healthcare M&A may increasingly become a market where premium assets command premium valuations while weaker operators struggle to attract strategic interest.

As a result, buyers are changing how they approach transactions.

Healthcare150's proprietary survey of 198 industry participants reveals a clear shift from expansion to precision. Across all respondents, the most common adaptation strategy is pursuing smaller platform deals combined with add-on acquisitions (24%), followed by structured or minority investments (21%), longer hold periods (21%), more selective sector focus (18%), and greater operational diligence before close (15%).

The variation by stakeholder group is particularly revealing.

Among C-suite leaders, 40% identified smaller platform deals with add-on strategies as their primary response to current market conditions, nearly double any other category. Corporate development leaders were even more decisive, with 67% reporting a more selective sector focus, suggesting organizations are concentrating capital in areas where they possess deeper expertise and stronger conviction.

Meanwhile, operational diligence has become increasingly important. Among healthcare M&A professionals, 50% identified greater pre-close operational diligence as the most important strategic adaptation, while 100% of investment management respondents selected deeper operational diligence before closing deals. The message is clear: financial engineering alone is no longer sufficient. Investors increasingly want visibility into physician retention, reimbursement exposure, labor dynamics, compliance infrastructure, and operational scalability before deploying capital.

This heightened focus on execution is also shaping perceptions of what will determine success after a deal closes.

Healthcare150's survey of 420 stakeholders reveals a remarkably balanced view of the factors most critical to successful healthcare M&A. Among all respondents, technology and data integration (26%) and physician alignment and talent retention (26%) tied as the leading success factors, followed closely by navigating reimbursement and regulation (24%) and post-close operational execution (23%).

The lack of a dominant answer reflects the growing complexity of healthcare transactions. Success is no longer determined by a single variable. Instead, value creation depends on managing several operational priorities simultaneously.

The differences across stakeholder groups are equally important. Among corporate development professionals, 47% identified physician alignment and talent retention as the single most important determinant of success, highlighting growing concerns around clinician engagement following acquisitions. Among C-suite executives, physician alignment also ranked highest at 31%, ahead of technology integration at 24%.

Healthcare M&A professionals see the market differently. Fully 50% identified technology and data integration as the most important success factor, reflecting the growing importance of interoperability, analytics, EMR integration, and data-driven decision making. Cardiologists offered another perspective, splitting their priorities evenly between reimbursement and regulation (33%) and post-close operational execution (33%), while only 11% selected technology integration.

Taken together, the findings suggest that modern healthcare M&A is increasingly an execution challenge rather than a capital markets exercise.

The same operational focus is influencing where investors expect healthcare M&A activity to remain strongest.

Healthcare150's proprietary survey found no overwhelming consensus regarding which healthcare subsectors will be most resilient over the next 12 months. Among all respondents, preferences were evenly distributed across value-based care models (26%), life sciences tools and services (26%), healthcare IT and data platforms (24%), and specialty care providers (24%).

However, stakeholder-specific preferences reveal where conviction is strongest.

Healthcare IT and data platforms emerged as the leading category among senior executives, with 42% of C-suite respondents selecting the segment as the most resilient area for M&A activity. Corporate development teams showed equal enthusiasm for healthcare IT and specialty care, with 40% selecting each category.

Among healthcare M&A professionals, however, specialty care providers stood out decisively. 67% identified specialty care as the most resilient healthcare M&A segment, while 50% of cardiologists shared that view. The strong support reflects continued confidence in outpatient, procedure-driven specialties that offer predictable demand, favorable reimbursement characteristics, and attractive platform-building opportunities.

Meanwhile, value-based care continues to attract investor interest, particularly among investment management respondents, where 28% selected the category as the most resilient segment. However, enthusiasm appears more measured than in previous years, suggesting that investors are increasingly prioritizing proven economics and demonstrated outcomes over growth narratives alone.

Even with growing confidence in select subsectors, concerns about risk continue to shape transaction activity.

Healthcare150's latest survey demonstrates that the healthcare M&A market remains constrained less by opportunity and more by uncertainty. Across all respondents, integration risk emerged as the leading concern at 29%, followed by financing costs (26%), regulatory uncertainty (24%), and valuations (21%).

The aggregate numbers, however, mask substantial differences across stakeholder groups.

Among corporate development leaders, 44% identified integration risk as the primary constraint, reflecting concerns about successfully absorbing new acquisitions without disrupting operations. Healthcare M&A professionals expressed a different concern altogether, with 67% identifying financing costs as the biggest challenge, underscoring the ongoing impact of higher borrowing costs and tighter leverage assumptions.

Cardiologists focused overwhelmingly on regulation, with 56% identifying regulatory uncertainty as the largest obstacle to M&A activity. For clinical stakeholders, concerns around reimbursement policy, antitrust scrutiny, and evolving healthcare regulations remain front and center.

Interestingly, valuations ranked lower than many industry observers might expect. While pricing discipline remains important, respondents consistently placed greater emphasis on execution, financing, and regulatory challenges. This suggests that healthcare buyers remain willing to transact when strategic fit and operational quality are present.

The overall picture that emerges from Healthcare150's research is one of disciplined optimism. Confidence is improving, deal activity is recovering, and capital remains available. Yet the market is operating under a fundamentally different set of rules than it did during the peak years of healthcare dealmaking.

The next phase of healthcare M&A will likely reward organizations that combine strategic clarity with operational excellence. Buyers are increasingly prioritizing physician retention, technology integration, reimbursement visibility, and execution readiness alongside traditional financial metrics. Scale alone is no longer enough. In today's environment, the assets most likely to command premium valuations are those capable of demonstrating sustainable economics, operational maturity, and a clear path to successful integration.

Healthcare M&A is recovering. But unlike previous cycles, the winners will not necessarily be the fastest-growing organizations. They will be the most defensible, the most scalable, and the most operationally prepared.

Sources & References

Healthcare150. (2026). What’s really holding back healthcare M&A? https://www.healthcare150.com/p/what-s-really-holding-back-healthcare-m-a 

Healthcare150. (2026). Healthcare M&A Strategy Is Shifting Toward Discipline. https://www.healthcare150.com/p/healthcare-m-a-strategy-is-shifting-toward-discipline 

Healthcare150. (2026). What Will Matter Most for Successful Healthcare M&A in This Cycle? https://www.healthcare150.com/p/what-will-matter-most-for-successful-healthcare-m-a-in-this-cycle 

Healthcare150. (2026). Where Healthcare M&A Is Most Likely to Hold Up in 2026. https://www.healthcare150.com/p/where-healthcare-m-a-is-most-likely-to-hold-up-in-2026 

Healthcare150. (2026). What Will Really Slow Healthcare M&A in the Next 12 Months? https://www.healthcare150.com/p/what-will-really-slow-healthcare-m-a-in-the-next-12-months 

KPMG. (2025). M&A trends in healthcare. https://kpmg.com/us/en/articles/mergers-acquisitions-trends-healthcare-life-sciences.html 

McKinsey. (2026). US healthcare: Companies continue to create value through diversification. https://www.mckinsey.com/capabilities/m-and-a/our-insights/us-healthcare-companies-continue-to-create-value-through-diversification 

PwC. (2026). Global M&A trends in health industries. https://www.pwc.com/gx/en/services/deals/trends/health-industries.html